Clonal Characteristics of Cutaneous T Cell Lymphomas: Cytogenetic Evidence from Blood, Lymph Nodes, and Skin  by Nowell, Peter C. et al.
0022-202X/82/7801-0069$02.00/0 
THE JOURNAL OF I NVESTIGATIVE D ERMATOLOGY, 78:69-75, 1982 
Copyright © 1982 by The Williams & Wilkins Co. 
Vol. 78, No.1 
Printed in U.S.A. 
Clonal Characteristics of Cutaneous T Cell Lymphomas: Cytogenetic 
Evidence from Blood, Lymph Nodes, and Skin 
PETER C. NOWELL, M.D., JANET B. FINAN, B.S., AND ERIC C. VONDERHEID, M.D. 
Department of Pathology and Laborat01y Medicine (PCN, JBF), School of Medicine, University of Pennsylvania, and Department of 
Dermatology (ECV), Temple University Health Sciences Center, Philadelphia, Pennsylvania, U.S.A. 
Chromosome studies were done on mitogen-stimulated 
lymphocytes from one or more tissues (blood, lymph 
nodes, skin lesions) in 15 patients with mycosis fungoides 
or Sezary syndrome. A cytogenetically abnormal clone 
was found in 10 individuals, including 6 with data from 
several tissues. In 4 cases the same aberrant clone was 
identified in a skin lesion as well as in blood and/ or 
lymph node. The abnormal chromosome patterns ranged 
from hypodiploid to hypertetraploid, and there was no 
evidence of unrelated karyotypically-altered lines at dif-
ferent sites. A 6q- chromosome, previously reported in 
acute lymphocytic leukemia, was found in 2 patients. 
The results support the concept that cutaneous T cell 
lymphomas (CTCL) are clonal disorders, presumably un-
ifocal in origin, with the skin lesions populated by cells 
from the same neoplastic clone that involves lymph 
nodes and blood. 
It is now widely recognized that most lymphomas which 
ext ensively involve the skin have T cell characteristics, and so 
mycosis fungo ides, Sezary syndrome, and related disorders have 
been grouped together as "cutaneous T cell lymphoma" 
(CTCL) [1,2]. B ecause multiple cutaneous lesions are a frequent 
early finding, before evidence of involvement of other organs, 
these disorders have been considered multifocal in origin, aris-
ing in the skin. Recently, however, some, but not all, cytogenetic 
studies of CTCL with modern banding techniques have sug-
gested a unicellular origin [3-7]. These investigations h ave been 
almost exclusively limited to blood and lymph nodes, and, 
except for a single patient [5], the karyotype of neoplastic 
lymphocytes in skin lesions has not been determined. 
We have done chromosom e studies on 15 patients with 
CTCL, including 6 in whom it was possible to obtain dividing 
lymphocytes from cutaneous lesions as well as blood or nodes. 
The results support the conclusion that CTCL is usually a 
clonal disorder , and further indicate that th e neoplastic lym-
phocytes in skin lesions are a part of th e same clone that 
involves extracutaneous sites. 
MATERIALS AND METHODS 
Patients 
Fifteen patients with the clinical and histologic features of CTCL 
(mycosis fungoides or Sezary syndrome) had cytogenetic studies 
(Tables I and II) . Eleven patients (9 males, 2 females) had manifesta-
tions of a generalized erythl'Oderma, and 3 of these individuals also had 
co-existing plaques or tumors. From a clinical standpoint, these patients 
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were classified as having Sezary synru·ome. The other 4 patients (2 
males, 2 females) had scattered plaques and tumors involving more 
than 10%.of the skin sw-face. These patients were classified as having 
tumor-phase mycosis fungoides. The median age of the entire group 
was 64 yr. 
Blood smeru·s, which were obtained at the same time as blood 
specimens for cytogenetic studies, were examined for the presence of 
mononucleru· cells with cerebriform nuclei (Sezru·y cells) (Table II). 
The cell diameters were measw·ed with an ocular micrometer and 
subclassified as small (8 to 11 J.1.111), intermediate (12 to 14 J.Lm), or large 
(15 to 19 J.1.111), since cell size is a useful criterion to distinguish between 
neoplastic and reactive T-lymphocytes in the blood [8). In this series, 
10 patients with eryth.rodermic CTCL and one patient with tumorous 
CTCL had more than 10% Sezary cells in the circulating lymphocyte 
pool, including cells with intermediate and lru·ge diameters, a finding 
which we feel is indicative of a neoplastic T-cell population in the 
blood. 
Cytogenetic Methods 
Peripheral blood specimens were cultured for 24 hr without mitogen 
or for 72-96 h1· with mitogen, using standard techniques for whole blood 
[9]. The mitogens included phytohemagglutinin (PHA-M, Difco, 50 J.Lg/ 
ml) , concanavalin A (Con A, Calbiochem, 50 J.Lg/ ml), the calcium 
ionophore A23187 (Lilly, 1 mM), and the tumor promoter, tetradeca-
noyl-0-phorbol-13-acetate (TPA, Chemical Cru·cinogenesis, 50 ng/ ml). 
There was little variation in the proliferative responses of a particulru· 
patient's cells to these different mitogens; responses to pokeweed 
mitogen (PWM) or Staphylococcus A, which were also used in a few 
instances, were typically much reduced. 
Biopsies of lymph nodes and skin lesions were fine ly minced and 
passed through a wire mesh to release lymphocytes as a single ceU 
suspension. These were then cultw-ed in the same fashion as the blood 
specimen [9). In one instance (patient JB), a "feeder" cul ture technique 
[10) was used to obtain adequate numbers of metaphases from several 
skin lesions which yielded only a few lymphocytes. In this n'!ethod, 
10,000 lymphocytes fTom the patient were mixed with 2.5 x 10'' mi to-
mycin-treated lymphocytes from a normal individual (of opposite sex 
to provide a chromosomal control) and the cultw-es were then stinm-
lated with PHA or TPA. The feeder cells did not proliferate, and the 
patient's lymphocytes proceeded through multiple sequential divisions 
[10) and were hru·vested after 6 or 7 days in cultw-e. 
Chromosome prepru·ations were prepru·ed in routine fashion fTom all 
cultures and examined with standru·d Giemsa staining ru1d with G-
banding [9]. Wherever possible, at least 30 chromosome counts and 5 
banded karyotype analyses were done on each specimen, with addi-
tional counts and analyses done as required to characterize specific 
cytogenetic abnormalities [11) and their clonal nature. 
RESULTS 
Chromosomally abnormal metaphases were observed in one 
or more tissues from ten individuals, representing from 8% to 
100% of the cells examined (Table III). In all 10 cases, these 
a berrant cells appeared to constitute a clone, with the same, or 
related, abnormal karyotype. N o particular cytogenetic altera-
t ions occW'red with sufficient frequency in t his series of patients 
to appear sp ecifically related to CTCL. The predominant clone, 
· except for patients FS and SEH, was pseudodiploid or near 
diploid, and in 3 patients (GB, HH, VH) a related near-tetra-
ploid line constituted a minority of the metaphases examined 
(Fig 1 and 2). Karyotypic abnormalities previously reported as 
occurring nonrandomly in other neoplasms [12,13] were ob-
served in 3 instances: deletions of th e long arm of chromosome 
6 (6q- ) in patients JB and FS (Fig 3- 5), and an isoclu·omosome 
for the long arm of 17 (i[17q]) in patient JM. 
69 
70 NOWELL ET AL Vol. 78, No. 1 
TABLE I. Clinical Features of 15 patients with CTCL 
Patient Age, Race, Duration of Stage" Previous therapy" Appearance of skin Lymph node Response to trea tmem/ Sex disease (yr) size·· 
. current sta tu " 
JM 6lBM 3 IVA CHL Erythroderma + PR/ Died OcL. 77 
DO 82WM 2 III None E rythroderma + CR/ Alive GB 52WM 10 III TSEB, topical HN2, E rythroderma with +++ PR/ Alive 
SC, in t ravenous few plaques 
HN2, PUVA 
EB 54WF 3 III or IVA PUVA Erythroderma with 0 DP/Alive 
multiple plaques 
CT 79WM < 1 IVA None Erythroderma + CR/ Alive 
FS 60BF >20 IVA None Mu ltiple plaques ++ CR/ Alive 
and nodules 
MA 56WM 4 IVA SC, CTX, MAC Erythroderma +++ NR/Alive 
HH 61WM 2 IVA CHL, SC, MAC Erythroderma ++ NR/ D ied Mar. 80 SEH 64WM 2 IVA TSEB, Topical HN2, Multiple plaques ++ DP /Died Sept. 80 
MTX, CTX, SC a nd few tumors 
ww 73WM 1 IVA Topical HN2, MTX Erythroderma ++ PR/ Alive VH 54WF 5 lii SC, topical HN2, Erythroderma + CR/ Aiive 
MTX 
CA 64WF >20 IVA sc Mult iple plaques ++ CR/ Alive 
a nd one tumor 
SRH 65WM >20 liB or IVA Local x-ray Multiple plaques 0 DP/ Alive 
and tumors 
JB 71WM 9 IVA None Erythroderma a nd 1 ++ PH/Alive 
subcutaneous tu-
mor 
PS 73WM 7 III T opical HN2, SC E rythroderma + PH/ Alive 
"Staging classification according to National Mycosis Fungoides Group recommendations [17]. The presence of Sezary cells in the blood currently is not considered as a criterion for staging. 
"Treatment Codes: SC = systemic corticosteroids; HN2 = mechloretha mine; CTX = cyclophosphamide; CHL = chlorambuci.l ; MTX = 
methotrexate; MAC = mu ltiple agent systemic chemotherapy; PUV A = methoxsalen photochemotherapy; TSEB = tota l skin electron beam 
radiotherapy. 
,. Lymph node size codes: 0 = < 1 em diameter; + = 1 to 2 em dia meter; ++ = 2 to 4 em diamete r; +++ = > 4 em dia meter. 
"Treatment response after cytogenetic studies; PR = partial remission; CR = complete remission; NR = no response; DP = disease progression. 
TABLE II. Concurrent laboratory results of 15 patients with CTCL 
Biopsy results" 
WBC/ % 
Differential coun t on 100 lymphocytes 
Patient 
Skin Lymph node Lymphocytes'' Normal mor- Small Sezary Intermed iate Se- Large Sezary phology za ry 
JM MF MF 38700/68 44 41 15 0 DD MF RH 26700/87 8 19 64 9 GB MF DL 12200/40 20 36 35 9 EB MF ND 14900/68 60 10 13 17 CT C/WMF MF 11200/25 75 2 23 0 FS MF MF 9200/22 98 2 0 0 MA MF MF 14400/65 43 10 43 4 HH MF MF 81000/48' 38 6 50 6 SEH MF MF 4700/8 82 4 14 0 ww C/WMF C/WMF 6000/16 94 5 1 0 VH C/WMF DL 11400/9 77 2 18 3 
·cA MF MF 4900/29 99 1 0 0 SRH MF ND 7200/8 100 0 0 0 
.JB MF with MF 2100/29 23 6 58 13 possible 
LL'' 
PS MF DL 6600/24 87 5 7 1 
" Histologic diagno~is codes: MF = diagnostic for mycosis fungo ides; C/W MF = strongly suggestive of mycosis fungoides; DL = dermatopathic lymphadenitis; RH = reactive lymphoid hyperplasia; LL = lymphocytic lymphoma; ND = not done. 1
' Includes morphologically normal and abnormal lymphocytes (Sezary cells). 
'" Many of the Sezary cells from this patient were "blastic" in appearance. 
"Sections from a subcutaneous tumor showed a band- like infiltrate beneath the epidermis composed mostly of cells with round to angulated 
nuclei . 
The presence of cytogenetic alterations did not appear to be 
consistently related to the overall dUTation or stage of the 
disease, but may have been influenced by previous therapy. All 
4 patients (GB, MA, HH, SEH) who had previously received 
large doses of chemotherapy or radiation had multiple chro-
mosome abnormalities. By contrast, karyotypic changes were 
found in only 6 of the 11 patients who had minimal or no 
previous exposure to such agents. 
Chromosome data were obtained from the blood in 14 of the 
15 patients, and in 9 of these cases, results were also obtained 
from lymph nodes and/or cutaneous lesions. Of particular in-
terest are the 6 patients in whom there were adequate numbers 
of mitoses from skin lesions for comparison with the fi ndings in 
one or more other tissues, and these will be briefly discussed 
individually. 
T he clinical featm es of patient HH were unusual in that the 
skin manifestations suddenly changed 6 mo before study from 
a disseminated papulosquamous eruption to a generalized 
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Patient 
JM' 
DD 
GB 
EB 
FS 
MA 
HH 
SEH 
VH 
JB 
Date of study 
2/76 
9/77 
5/78 
(Partial remission) 
12/78 
(Complete remission) 
9/78 
7/79 
(Partial remission) 
7/80 
(Complete remission) 
4/ 79 
12/79 
2/80 
2/80 
3/80 
7/80 
9/80 
10/8o' 
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TABLE III. Chromosome abnormalities in 10 patients with CT CL 
Mitogen 
Abnormal cells/ tota l cells" 
Predominant abnormal karyotype" 
Blood Lymph Node Ski n Lesion 
PHA, A23187 17/58 7/ 47 47, XV, -9, -13, -17, -19, +del(9) 
+t(9;13), +t(9;19), +i(17q) , +?2 
PHA, A23187 20/ 101 46, XV, 2q+, abn 12 
PHA 18/ 25 46, XV, abn 12, 15q+ 
PHA, Con A 0/ 85 
PHA, A23187, 101/ 125 50, XV, -10, - 16, +2D, +4mar" 
Con A 
PHA 11/ 42 (Same) 
PHA 0/22 
PHA 5/75 46, XX, -B, -C, +2 mar 
PHA, PWM 0/ 24 12/ 49 9/ 10, 0/ 9 Hypertetraploid with minute 
markers 
PHA, PWM 6/ 21 3/ 37 46, XV, -1 , -10, +t(1;9), +t(JO;ll), 
9q - , uq-
PHA 16/ 19 15/23 9/ 16 42, XV, -2B, -3C, - 13, -21, -22," 
+?Bp+, +3Cq- , l p+, 1 7q+ 
(none) 13/ 13 28/ 32 
PHA 31/ 31 15/15 Hypert riploid with extra 3 
(none) (Same) 
PHA, TPA 94/117 50, XX, -15, + 3q- +6q- , +9, +21", 
+mar, lq+, 2p-
PHA, TPA 61 / 65 2/ 33 4/ 60'' 46, XV, 6q- , abn 12 
PHA, TPA 6/ 35 13/ 19" (Same) 
" Abnormal cells = Cells with predominant, or related, abnormal karyotype. 
" Karyotypic findings are expressed in standard nomenclature (11]: p = short arm, 'q = long arm, del = deletion, t = translocation, i = 
isochromosome, mar = marker. 
,. Previously reported (9]. 
" A subline with near-tetraploid chromosome number constituted 10-25% of metaphases examined. 
" Feeder cu ltures, grown 6-7 days. AU other cultures grown 24 hours without mitogen or 72-96 hours with mitogen. 
r Direct bone marrow preparation had 0/ 29 abnormal cells. 
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FrG 1. Representative G-banded metaphase of clone with 42 chromosomes from a lymph node of patient HH. T here are multiple abnormali ties 
(see Table III) , including a distinctive 17q+ marker chromosome (w.,.ow). 
FIG 2. Portion of a representative G-banded metaphase with 84 chromosomes from the same node as Fig 1. Note two 17q+ markers (wTows), 
indicating that this minority population of hypotetraploid cells was a subline of the hypodiploid clone illustrated in Fig 1. T he same 2 related 
populations, with 17q+ markers, were identified in blood and a skin lesion. 
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FIG 3. Representative G-banded abnormal karyotype from the blood of patient JB. Note 6q- clu·omosome and abnormall2, perhaps resulting from insertion of 12p into 12q (arrows). 
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FIG 4. Representative G-banded karyotype of lymphocyte from an erythematous skin lesion of patient JB. Note same aberrations (6q-, 
abnormall2) as in the blood (Fig 3), indicating the same neoplastic clone in both tissues (arrows). This cell also has an Sq+ (found in one other 
cell from this lesion and perhaps indicating a minority subline) and random loss of a number 16. 
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FIG 5. Representative G-banded abnormal karyotype from blood of patient VH interpreted as: 50,XX,-15, +3q- , +Gq- ,+9,+ 21, 
+ mar,lq+,2p- ,lop- . Note 6q - chromosome (arrow), perhaps with material translocated hom the missing 15, in addition to both normal 6's. A 6q-
abnormality was also present in patient JB (Fig 3, 4), and has been observed previously in acute lymphocytic leukemia [1 2). 
erythroderma accompanied by a rapidly rising white blood cell 
count composed mostly of eosinophils and Sezary cells, many 
of which had a "blastic" nuclear appearance. Previous treat-
ment with chlorambucil and then multiple agent chemotherapy 
had been ineffective. Chromosome studies revealed a hypodip-
loid line with 42 chromosomes and multiple rearrangements 
involving the majority of the meta phases examined from blood, 
inguinal lymph node, and erythematous skin from the upper 
left leg. A related hypotetraploid line, with approximately 84 
chromosomes and many of the same rearrangements, including 
a 17q+ marker chromosome, were a small minority of the 
dividing cells in all of these tissues (Fig 1 and 2). 
Patient SEH had rapidly progressive CTCL (tumor-phase 
mycosis fungoides) at the time of cytogenetic study. Blood 
smears showed substantial numbers of Sezary cells, consistent 
with the leukemic phase of the disease (Table II) . Cytogenetic 
analysis of lymphocytes obtained from a left axillary node and 
a thick plaque on the scalp demonstrated a hypotetraploid 
clone, with approximately 72 chromosomes, tetraploidy for 
chromosome 3, and extra chromosomes in group G. 
Patient FS had had evidence of cutaneous disease for more 
than 20 yr and began to develop plaques and nodular lesions 5 
yr prior to her initial evaluation. Cluomosome data were ob-
tained from 2 different skin lesions, as well as from blood and 
lymph nodes. A hypertetraploid clone with two abnormal min-
ute chromosomes was identified in a skin lesion on the upper 
right leg and in a right inguinal lymph node. Metaphases from 
a skill lesion of the left leg, however, had a normal karyotype, 
as did lymphocytes from the peripheral blood, which contained 
only rare Sezary cells (Table II) . 
Patient JB had a complicated clinical history. In 1971, he 
developed a nasopharyngeal mass which was diagnosed as 
lymphosarcoma, with no additional studies performed for B-
cell or T-cell markers. He was followed without additional 
treatment and shortly thereafter developed a mild genel"alized 
erythroderma with persistent lymphocytosis. In 1980, a subcu-
taneous tumor developed on the lower left leg, and a biopsy 
revealed a deep-seated infiltrate of cells resembling the original 
"poorly differentiated lymphocytic lymphoma." Biopsies from 
other erythematous skin areas, as well as 2 inguinal lymph 
nodes, were considered more consistent with the diagnosis of 
CTCL. Blood smears showed numerous Seza.ry cells, and elec-
tron microscopy confirmed that many lymphocytes had irreg-
ular, highly infolded nuclei. As indicated in Table III, a pseu-
dodiploid clone, with abnormalities of chromosomes 6 and 12, 
constituted most of the dividing cells from this patient's periph-
eral blood and from an erythematous skin area of the thigh; 
but these abnormal cells were only a small minority of the 
metaphases in two lymph nodes and in the subcutaneous tumor 
of the left calf (Fig 3 and 4). The cytogenetic data dearly 
indicate the same neoplastic clone in the blood and eryt~ema­
tous skin, but the low frequency (7-17%) of such cells m th.e 
lymph nodes and skin tumor could simply represent contami-
nation by circulating elements. It is tempting to speculate that 
the normal metaphases in the nodes and skin tumor represe~t 
an earlier stage of the neoplasm in this patient, similar to his 
original lymphoma, and that the chromosomally abnormal cells 
are an evolved subline, perhaps having acquired a grea_ter 
propensity to infiltrate the skin and to recirculate, prod.ucmg 
the diffuse generalized erythroderma and the blood picture 
characteristic of Sezary syndrome. Direct bone marrow prepa-
rations were chromosomally normal, but the marrow contained 
no aberrant lymphocytes and was not stimulated by mitogen. 
The other 2 patients on whom cytogenetic data were obtained 
from the skin (CA, SRH) had long-standing cutaneous mani-
festations typical of tumor-phase mycosis fungoides, and nei-
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ther had aberrant chromosomes. In patient CA, a normal kar-
yotype was observed in cells from blood (60 metaphases ex-
amined), lymph node (68 metaphases), and a skin tumor (31 
metaphases). There were no Sezary cells in the blood, but the 
skin lesion and the recently enlarged inguinal node on which 
chromosome studies were done showed mycosis fungoides his-
tologically. Patient SRH was similar, except for absence of any 
clinical evidence of extracutaneous disease. The cytogenetic 
pattern was normal both in blood (no Sezary cells) and in a 
skin tumor which was histologically neoplastic (31 and 52 
metaphases, respectively). 
Among the 9 patients without karyotypic data from skin 
lesions, there were 3 additional individuals who did not have 
chromosome abnormalities (CT, PS, WW) although they did 
have Sezary cells in the peripheral blood. In patients CT and 
PS, 67 and 51 metaphases were examined from the blood, and 
19 and 65 cells from lymph nodes; the node from patient CT 
was histologically involved with CTCL, but the one from patient 
CS was not. In patient WW, only blood was studied; 27 normal 
metaphases from mitogen-stimulated cultures, and 8 normal 
metaphases from 24-hr cultures without mitogen. 
In general, the presence of substantial numbers of Sezary 
cells on blood smears correlated with abnormal cytogenetic 
findings on concurrent peripheral blood specimens. Karyotypic 
alterations were found in 7 of 9 patients who had more than 
10% Sezary cells in the circulating lymphocyte pool (Table II). 
This correlation was also evident in 2 patients on whom serial 
studies were done. The frequency of both hyperdiploid and 
hypotetraploid cells detected cytogenetically in the blood of 
patient GB decreased following therapy, and they were totally 
absent when remission was achieved. During the same period, 
Sezary cells in the blood smear also declined and then disap-
peared. In the other patient followed serially (DD), there was 
a change in the chromosome constitution of the predominant 
pseudodiploid clone following therapy, and these aberrant cells 
also disappeared from the peripheral blood when remission was 
achieved and Sezary cells could no longer be detected on routine 
smears (Table III) . 
DISCUSSION 
Our findings in 15 patients indicate that most, but not all, 
cases of CTCL are karyotypically abnormal, with the clonal 
nature of these disorders indicated by the cytogenetic data. In 
the 10 individuals with chromosome alterations, the changes 
differed from case to case, but within each patient the aberrant 
cells had the same, or related, abnormal karyotype; and in 6 
cases, t his was observed in more than one tissue. These results 
·confrrm and extend conclusions on the clonal nature of CTCL 
frpm most of the few previous cytogenetic reports which utilized 
modern banding methods [3-7], as well as from a recent study 
with monoclonal antibodies directed against T-cell antigens 
[14]. 
In the present series, the chromosome alterations were quite 
extensive in a number of individuals, including several who had 
related sublines in the diploid and polyploid range. There was 
no suggestion of · nonrandom changes specifically related to 
CTCL, but several abnormalities previously reported in other 
human tumors were observed. In 2 patients (JB, VH) there was 
a deletion in the long arm of chromosome 6 (6q- ) (Fig 3-5), an 
alteration which has been described as occurring non-randomly 
in acute lymphocytic leukemia [12,13]. One patient (JM) , re-
ported in detail elsewhere [9], had an isochromosome for the 
long arm of 17 (i[17q]) , a common abnormality in a variety of 
human hematopoietic neoplasms [13]. There were no examples 
of an alteration involving the terminal portion of the long arm 
of chromosome 14 (14q+), although this aberration occurs with 
high frequency in many B-cell neoplasms, and has been re-
ported in chronic T-cellleukemia [13,15]. 
Patients previously exposed to large doses of mutagenic ther-
apy seemed, in general, to have more extensive chromosome 
abnormalities, both in this series and in previous studies [ 4-6]. 
Vol. 78, No. 1 
This observation may indicate a role of mu tagenic therapy in 
the cytogenetic evolution of neoplastic clones, but it is also 
possible that the patients requiring such aggressive treatment 
were those with disease already karyotypically abnormal. 
It is difficult to be certain whether, in the 5 patients who did 
not have chromosome abnormalities, the dividing lymphocytes 
examined represented a diploid neoplasm or nonneoplastic cells. 
In some cases at least, spontaneous proliferation of the lympho-
cytes in culture, or their derivation from histologically neoplas-
tic lesions, suggests that they were indeed CTCL cells with a 
normal karyotype . 
Although Edelson et al [5] found related aberrant karyotypes 
in 2 subcutaneous tumors from a patient with mycosis fun-
goides, the present study represents the first series in which the 
chromosomal alterations in lymphocytes from skin lesions of 
CTCL have been correlated with the findings at other sites. 
This proved technically feasible in 6 patients, using either 
standard lymphocyte culture techniques or a feeder m eth od 
[10] which can generate adequate numbers of mitoses from a 
very small inoculum of cells. Several T-cell mitogens were used 
in this investigation (PHA, Con A, A23187, TPA), without 
major differences in the response of chromosomally abnormal 
cells to the various mitogens, although such differences have 
been noted in some chronic T-cell neoplasms [15]. In limited 
studies, we did not obtain the good proliferation with PWM or 
Staph A which has been reported in CTCL by others [16]. 
In all 6 patients with chromosome data from skin lesions, the 
findings correlated with the results from blood and/or lymph 
nodes. In 4 patients (FS, HH, SEH, JB), the same cytogeneti-
cally abnormal clone was observed in lymphocytes from a 
cutaneous lesion and from at least one other tissue; and in the 
remaining 2 patients (CA, SRH) , the karyotype was normal in 
all tissues examined. In 2 cases (FS, JB), the data included 
some tissues without any aberrant cells (Table III) , but in no 
circumstance was there evidence of unrelated karyotypically 
abnormal lines at different sites. 
The present findings support the view that, at least at the 
stage of disease studied in this series, CTCL represents a 
monoclonal process, with neoplastic cells in the skin, lymph 
nodes, and blood being elements of the same clone. The data 
no not rule out the possibility that these disorders in an initial 
cutaneous phase could have been multifocal, with subsequent 
overgrowth and extracutaneous spread from a single aggressive 
focus. It may be significant, however, that the observations in 
one unusual circumstance (patient JB) suggest that a tumor 
which was originally a localized nasopharyngeal lymphosar-
coma evolved to the Sezary syndrome. Unfortunately, since the 
present lymphosarcomatous elements in. this patient appeared 
to have a normal karyotype, it cannot be stated categorically 
that the pseudodiploid Sezary cells represent a later stage of 
the same neoplastic clone. 
With the availability of techniques for studying cytogeneti-
cally the cells of CTCL from various sites and over prolonged 
periods of time, it should be possible to gain further insight 
into the natural history of these disorders. It will be of interest 
to find whether there is cytogenetic evidence of clonal evolution 
in different lesions at varying stages of progression, and also 
whether the chromosome patterns observed can be of diagnostic 
or prognostic value in the management of these patients. 
We thank Adam Guttentag, Marybeth Helti·ich, and Sherri Shiger 
for expert technical assistance. 
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